Haemophilia

Haemophilia is a bleeding disorder that affects the body's ability to form blood clots. This condition is usually genetically inherited and affects mostly males. People with haemophilia lack specific proteins that are necessary for clotting. As a result, they may bleed for longer periods than others who do not have the condition. Haemophilia is generally classified into two types, haemophilia A and B. Haemophilia A is the most common type and is caused by a deficiency in clotting factor VIII, while haemophilia B is caused by a deficiency in clotting factor IX. Both types of haemophilia can cause similar symptoms such as spontaneous bleeding into muscles or joints, leading to pain, swelling, stiffness, and restricted movement. As a result of the advanced molecular and genetic techniques that are being developed, haematology and oncology researchers have made significant strides in the diagnosis and management of haemophilia. The development of recombinant coagulation factors, hemostatic agents, gene therapy and other pharmacological therapies has revolutionized the treatment of haemophilia, allowing patients to lead a better quality of life. Oncology and haematology researchers are also exploring ways to treat haemophilia through gene therapy, which offers the possibility of a cure by replacing the faulty gene that is responsible for the condition. This approach has shown encouraging results in clinical trials and offers hope for people living with haemophilia. In conclusion, haemophilia is a chronic condition that requires ongoing management and care. However, thanks to the work of haematology and oncology researchers, people with haemophilia can now enjoy a better quality of life, and there is hope for a cure in the future.